Molecular mechanisms of chemoresistance in osteosarcoma (Review)
Tóm tắt
Từ khóa
Tài liệu tham khảo
Chou, 2006, Chemotherapy resistance in osteosarcoma: current challenges and future directions, Expert Rev Anticancer There, 6, 1075, 10.1586/14737140.6.7.1075
Longhi, 2006, Primary bone osteosarcoma in the pediatric age: state of the art, Cancer Treat Rev, 32, 423, 10.1016/j.ctrv.2006.05.005
Chou, 2008, Therapy for osteosarcoma: where do we go from here?, Paediatr Drugs, 10, 315, 10.2165/00148581-200810050-00005
Eilber, 1989, Adjuvant chemotherapy for osteosarcoma, Semin Oncol, 16, 312
Sakamoto, 2008, Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy, Rev Recent Clin Trials, 3, 228, 10.2174/157488708785700267
Bertino, 1993, Karnofsky memorial lecture. Ode to methotrexate, J Clin Oncol, 11, 5, 10.1200/JCO.1993.11.1.5
Hattinger, 2003, Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques, Eur J Cell Biol, 82, 483, 10.1078/0171-9335-00336
Guo, 1999, Mechanisms of methotrexate resistance in osteosarcoma, Clin Cancer Res, 5, 621
Patiño-García, 2009, Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression, J Pediatr, 154, 688, 10.1016/j.jpeds.2008.11.030
Ifergan, 2003, Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity, Cancer, 98, 1958, 10.1002/cncr.11741
Flintoff, 2004, Functional analysis of altered reduced folate carrier sequence changes identified in osteosarcomas, Biochim Biophys Acta, 1690, 110, 10.1016/j.bbadis.2004.05.008
Serra, 2004, Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells, Ann Oncol, 15, 151, 10.1093/annonc/mdh004
Yang, 2003, Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples, Clin Cancer Res, 9, 837
Trippett, 1999, High dose trimetrexate with leucovorin protection in recurrent childhood malignancies: a phase II trial, J Clin Oncol (ASCO Annual Meeting Abstracts), 9, 889
Weinstein, 1990, P-glycoproteins in pathology: the multidrug resistance gene family in humans, Hum Pathol, 21, 34, 10.1016/0046-8177(90)90073-E
Safa, 1990, Molecular basis of preferential resistance to colchicine in multidrug-resistant human cells conferred by Gly-185→Val-185 substitution in P-glycoprotein, Proc Natl Acad Sci USA, 87, 7225, 10.1073/pnas.87.18.7225
Bramwell, 2000, osteosarcomas and other cancers of bone, Curr Opin Oncol, 12, 330, 10.1097/00001622-200007000-00009
Park, 2001, The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma, Int Orthop, 24, 307, 10.1007/s002640000196
Gomes, 2006, Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studies, Nucl Med Biol, 33, 831, 10.1016/j.nucmedbio.2006.07.011
Serra, 2006, May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol, Int J Oncol, 29, 1459
Baldini, 1999, P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy, J Orthop Res, 17, 629, 10.1002/jor.1100170502
Kusuzaki, 1999, Relationship between P-glycoprotein positivity, doxorubicin binding ability and histologic response to chemotherapy in osteosarcomas, Cancer Lett, 138, 203, 10.1016/S0304-3835(99)00018-X
Trammell, 2000, Multidrug resistance-1 gene expression does not increase during tumor progression in the MGH-OGS murine osteosarcoma tumor model, J Orthop Res, 18, 449, 10.1002/jor.1100180318
Wunder, 2000, MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study, J Clin Oncol, 18, 2685, 10.1200/JCO.2000.18.14.2685
Pakos, 2003, The association of P-glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma. A meta-analysis, Cancer, 98, 581, 10.1002/cncr.11546
Sorensen, 2008, Immunohistochemical estimates of angiogenesis, proliferative activity, p53 expression, and multiple drug resistance have no prognostic impact in osteosarcoma: A comparative clinicopathological investigation, Sarcoma, 2008, 874075, 10.1155/2008/874075
Takeshita, 2000, Osteoblastic differentiation and P-glycoprotein multidrug resistance in a murine osteosarcoma model, Br J Cancer, 82, 1327, 10.1054/bjoc.1999.1099
Susa, 2010, Inhibition of ABCB1 (MDR1) expression by an siRNA nanoparticulate delivery system to overcome drug resistance in osteosarcoma, PLoS One, 5, e10764, 10.1371/journal.pone.0010764
Susa, 2009, Doxorubicin loaded polymeric nanoparticulate delivery system to overcome drug resistance in osteosarcoma, BMC Cancer, 9, 399, 10.1186/1471-2407-9-399
Kobayashi, 2013, Lipid-functionalized dextran nanosystems to overcome multidrug resistance in cancer: a pilot study, Clin Orthop Relat Res, 471, 915, 10.1007/s11999-012-2610-2
Townsend, 2003, The role of glutathione-S-transferase in anti-cancer drug resistance, Oncogene, 22, 7369, 10.1038/sj.onc.1206940
Tew, 1994, Glutathione-associated enzymes in anticancer drug resistance, Cancer Res, 54, 4313
Shoieb, 1997, Detection and significance of glutathione-S-transferase pi in osteogenic tumors of dogs, Int J Oncol, 10, 635
Uozaki, 1997, Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis, Cancer, 79, 2336, 10.1002/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J
Wei, 2006, Expression of MDR1 and GST-pi in osteosarcoma and soft tissue sarcoma and their correlation with chemotherapy resistance, Zhonghua Zhong Liu Za Zhi, 28, 445
Bruheim, 2004, Human osteosarcoma xenografts and their sensitivity to chemotherapy, Pathol Oncol Res, 10, 133, 10.1007/BF03033741
Huang, 2007, Expression of human glutathione S-transferase P1 mediates the chemosensitivity of osteosarcoma cells, Mol Cancer Ther, 6, 1610, 10.1158/1535-7163.MCT-06-0580
Windsor, 2012, Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study, Cancer, 118, 1856, 10.1002/cncr.26472
Zhang, 2012, Predictive potential of glutathione S-transferase polymorphisms for prognosis of osteosarcoma patients on chemotherapy, Asian Pac J Cancer Prev, 13, 2705, 10.7314/APJCP.2012.13.6.2705
Yang, 2012, Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors, Asian Pac J Cancer Prev, 13, 5883, 10.7314/APJCP.2012.13.11.5883
Pasello, 2008, Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma, Cancer Res, 68, 6661, 10.1158/0008-5472.CAN-07-5840
Pasello, 2011, Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy, Anal Cell Pathol (Amst), 34, 131, 10.1155/2011/414985
Sau, 2012, Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines, Mol Biosyst, 8, 994, 10.1039/C1MB05295K
Sak, 2005, APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer, Clin Cancer Res, 11, 6205, 10.1158/1078-0432.CCR-05-0045
Silber, 2002, The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress, Clin Cancer Res, 8, 3008
Yang, 2005, Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (Ape/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an Ape1/Ref-1 inhibitor, Mol Cancer Ther, 4, 1923, 10.1158/1535-7163.MCT-05-0229
Wang, 2004, Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition, Mol Cancer Ther, 3, 679, 10.1158/1535-7163.679.3.6
Wang, 2007, Vector-based Ape1 small interfering RNA enhances the sensitivity of human osteosarcoma cells to endostatin in vivo, Cancer Sci, 98, 1993, 10.1111/j.1349-7006.2007.00616.x
Yang, 2010, APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival, Technol Cancer Res Treat, 9, 161, 10.1177/153303461000900205
Luo, 2004, Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone, Anticancer Res, 24, 2127
Madhusudan, 2005, Isolation of a small molecule inhibitor of base excision repair, Nucleic Acids Res, 33, 4711, 10.1093/nar/gki781
Seiple, 2008, Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids, Mol Pharmacol, 73, 669, 10.1124/mol.107.042622
Fishel, 2007, The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target, Mol Aspects Med, 28, 375, 10.1016/j.mam.2007.04.005
Nathrath, 2002, Expression of genes of potential importance in the response to chemotherapy in osteosarcoma patients, Klin Padiatr, 214, 230, 10.1055/s-2002-33189
Li, 2007, Expressions of ERCC2 and ERCC4 genes in osteosarcoma and peripheral blood lymphocytes and their clinical significance, Beijing Da Xue Xue Bao, 39, 467
Caronia, 2009, Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients, Pharmacogenomics J, 9, 347, 10.1038/tpj.2009.19
Biason, 2012, Nucleotide excision repair gene variants and association with survival in osteosarcoma patients treated with neoadjuvant chemotherapy, Pharmacogenomics J, 12, 476, 10.1038/tpj.2011.33
Hao, 2012, Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients, Asian Pac J Cancer Prev, 13, 3821, 10.7314/APJCP.2012.13.8.3821
Meric-Bernstam, 2009, Targeting the mTOR signaling network for cancer therapy, J Clin Oncol, 27, 2278, 10.1200/JCO.2008.20.0766
Gordon, 2008, Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs, Am J Vet Res, 69, 1079, 10.2460/ajvr.69.8.1079
Gazitt, 2009, Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways, Int J Oncol, 34, 551
Zhou, 2010, mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients’ prognosis, Med Oncol, 27, 1239, 10.1007/s12032-009-9365-y
Houghton, 2008, Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program, Pediatr Blood Cancer, 50, 799, 10.1002/pbc.21296
Wan, 2005, Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma, Cancer Res, 65, 2406, 10.1158/0008-5472.CAN-04-3135
Mu, 2013, Rapamycin inhibits ALDH activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells, Sarcoma, 2013, 480713, 10.1155/2013/480713
LeRoith, 2003, The insulin-like growth factor system and cancer, Cancer Lett, 195, 127, 10.1016/S0304-3835(03)00159-9
Chitnis, 2008, The type 1 insulin-like growth factor receptor pathway, Clin Cancer Res, 14, 6364, 10.1158/1078-0432.CCR-07-4879
Chou, 2005, Analysis of aberrant signal transduction pathways in osteosarcoma cell lines, Proc Amer Assoc Cancer Res, 46, 4551
Scotlandi, 2005, Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors, Cancer Res, 65, 3868, 10.1158/0008-5472.CAN-04-3192
Tanno, 2006, Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo, Clin Cancer Res, 12, 6772, 10.1158/1078-0432.CCR-06-1479
Hassan, 2012, Cell surface receptor expression patterns in osteosarcoma, Cancer, 118, 740, 10.1002/cncr.26339
Luk, 2011, IGF1R-targeted therapy and its enhancement of doxorubicin chemosensitivity in human osteosarcoma cell lines, Cancer Invest, 29, 521, 10.3109/07357907.2011.606252
Wang, 2010, Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo, Mol Cell Biochem, 341, 225, 10.1007/s11010-010-0453-2
Rettew, 2012, Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines, Oncogenesis, 1, e34, 10.1038/oncsis.2012.34
Wang, 2012, Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma, J Surg Oncol, 105, 235, 10.1002/jso.22077
Gombos, 2012, Clinical development of insulin-like growth factor receptor-1 (IGF-1R) inhibitors: at the crossroad?, Invest New Drugs, 30, 2433, 10.1007/s10637-012-9811-0
Tap, 2010, AMG 479 in relapsed or refractory Ewing’s family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results, J Clin Oncol, 28, 10001, 10.1200/jco.2010.28.15_suppl.10001
Natinoal Institutes of HealthA Study to Determine the Activity of SCH 717454 in Subjects with Relapsed Osteosarcoma or Ewing’s Sarcoma (Study P04720AM3)http://clinicaltrials.gov/ct2/show/NCT00617890?term=sch-717454&rank=2Accessed April 6, 2011
Akatsuka, 2002, ErbB2 expression is correlated with increased survival of patients with osteosarcoma, Cancer, 94, 1397, 10.1002/cncr.10360
Zhou, 2011, VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma, Surg Oncol, 20, 13, 10.1016/j.suronc.2009.09.002
Maris, 2008, Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program, Pediatr Blood Cancer, 50, 581, 10.1002/pbc.21232
Ebb, 2012, Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group, J Clin Oncol, 30, 2545, 10.1200/JCO.2011.37.4546
Liebermann, 1995, Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways, Oncogene, 11, 199
Asada, 1999, De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line, Anticancer Res, 19, 5131
Wong, 2007, p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3, Mol Cancer Ther, 6, 1054, 10.1158/1535-7163.MCT-06-0336
Fan, 1999, Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair, Mol Pharmacol, 56, 966, 10.1124/mol.56.5.966
Tsuchiya, 2000, Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma, Anticancer Res, 20, 235
Sato, 2000, Enhancement of drug-induced apoptosis by antisense oligodeoxynucleotides targeted against Mdm2 and p21WAF1/CIP1, Anticancer Res, 20, 837
Tang, 2004, A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin, Br J Cancer, 90, 1285, 10.1038/sj.bjc.6601653
Goto, 1998, Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas, Jpn J Cancer Res, 89, 539, 10.1111/j.1349-7006.1998.tb03295.x
Pápai, 1997, P53 overexpression as an indicator of overall survival and response to treatment in osteosarcomas, Pathol Oncol Res, 3, 15, 10.1007/BF02893346
Ozger, 2009, The effect of resistance-related proteins on the prognosis and survival of patients with osteosarcoma: an immunohistochemical analysis, Acta Orthop Traumatol Turc, 43, 28, 10.3944/AOTT.2009.028
Wunder, 2005, TP53 mutations and outcome in osteosarcoma: a prospective, multicenter study, J Clin Oncol, 23, 1483, 10.1200/JCO.2005.04.074
Chao, 1998, BCL-2 family: regulators of cell death, Ann Rev Immunol, 16, 395, 10.1146/annurev.immunol.16.1.395
Korsmeyer, 1999, BCL-2 gene family and the regulation of programmed cell death, Cancer Res, 59, 1693s
Ye, 1998, bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection, J Urol, 160, 2025, 10.1016/S0022-5347(01)62233-X
Han, 1999, The relationship between cisplatin-induced apoptosis and p53, bcl-2 and bax expression in human lung cancer cells, Korean J Intern Med, 14, 42, 10.3904/kjim.1999.14.1.42
Luo, 1999, Chemosensitivity of human hepatocellular carcinoma cell line QGY-7703 is related to bcl-2 protein levels, Tumour Biol, 20, 331, 10.1159/000030097
Murata, 2004, Molecular mechanism of chemoresistance to cisplatin in ovarian cancer cell lines, Int J Mol Med, 13, 865
Perego, 1997, Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines, Apoptosis, 2, 540, 10.1023/A:1026442716000
Zhao, 2009, Enhanced chemosensitivity of drug-resistant osteosarcoma cells by lentivirus-mediated Bcl-2 silencing, Biochem Biophys Res Commun, 390, 642, 10.1016/j.bbrc.2009.10.020
Zhang, 2012, Enhanced chemosensitivity by simultaneously inhibiting cell cycle progression and promoting apoptosis of drug-resistant osteosarcoma MG63/DXR cells by targeting Cyclin D1 and Bcl-2, Cancer Biomark, 12, 155, 10.3233/CBM-130305
Dey, 2000, Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells, J Biol Chem, 275, 7087, 10.1074/jbc.275.10.7087
Zangemeister-Wittke, 2003, Antisense to apoptosis inhibitors facilitates chemotherapy and TRAIL-induced death signaling, Ann NY Acad Sci, 1002, 90, 10.1196/annals.1281.019
Zhang, 2000, Role of BAX in the apoptotic response to anticancer agents, Science, 290, 989, 10.1126/science.290.5493.989
Eliseev, 2008, Runx2-mediated activation of the Bax gene increases osteosarcoma cell sensitivity to apoptosis, Oncogene, 27, 3605, 10.1038/sj.onc.1211020
Cao, 2008, c-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis, J Biol Chem, 283, 14490, 10.1074/jbc.M801107200
Ferrari, 2004, Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma, Cancer, 100, 1936, 10.1002/cncr.20151
Wu, 2012, Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients, Cancer Epidemiol, 36, 212, 10.1016/j.canep.2011.08.002
Wang, 2010, Functional and biological analysis of Bcl-xL expression in human osteosarcoma, Bone, 47, 445, 10.1016/j.bone.2010.05.027
Nedelcu, 2008, Livin and Bcl-2 expression in high-grade osteosarcoma, J Cancer Res Clin Oncol, 134, 237, 10.1007/s00432-007-0276-z
Kaseta, 2008, Prognostic value of bax, bcl-2, and p53 staining in primary osteosarcoma, J Surg Oncol, 97, 259, 10.1002/jso.20913
Kaseta, 2007, Prognostic value of bax, cytochrome C, and caspase-8 protein expression in primary osteosarcoma, Hybridoma (Larchmt), 26, 355, 10.1089/hyb.2007.0519
Degenhardt, 2006, Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis, Cancer Cell, 10, 51, 10.1016/j.ccr.2006.06.001
Klionsky, 2000, Autophagy as a regulated pathway of cellular degradation, Science, 290, 1717, 10.1126/science.290.5497.1717
Maiuri, 2007, Self-eating and self-killing: crosstalk between autophagy and apoptosis, Nat Rev Mol Cell Biol, 8, 741, 10.1038/nrm2239
Kroemer, 2008, Autophagic cell death: the story of a misnomer, Nat Rev Mol Cell Biol, 9, 1004, 10.1038/nrm2529
Han, 2008, Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells, J Biol Chem, 283, 19665, 10.1074/jbc.M710169200
Amaravadi, 2007, Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma, J Clin Invest, 117, 326, 10.1172/JCI28833
Carew, 2010, Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation, J Cell Mol Med, 14, 2448, 10.1111/j.1582-4934.2009.00832.x
Wu, 2010, Autophagy blockade sensitizes prostate cancer cells towards Src family kinase inhibitors, Genes Cancer, 1, 40, 10.1177/1947601909358324
Li, 2010, Inhibition of autophagy augments 5-fluorouracil chemotherapy in human colon cancer in vitro and in vivo model, Eur J Cancer, 46, 1900, 10.1016/j.ejca.2010.02.021
White, 2009, The double-edged sword of autophagy modulation in cancer, Clin Cancer Res, 15, 5308, 10.1158/1078-0432.CCR-07-5023
Katayama, 2007, DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells, Cell Death Differ, 14, 548, 10.1038/sj.cdd.4402030
Carew, 2007, Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance, Blood, 110, 313, 10.1182/blood-2006-10-050260
Lambert, 2008, Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model, Cancer Res, 68, 7966, 10.1158/0008-5472.CAN-08-1333
Meschini, 2008, The plant alkaloid voacamine induces apoptosis-independent autophagic cell death on both sensitive and multidrug resistant human osteosarcoma cells, Autophagy, 4, 1020, 10.4161/auto.6952
Kim, 2013, Cytoprotective role of autophagy during paclitaxel-induced apoptosis in Saos-2 osteosarcoma cells, Int J Oncol, 42, 1985, 10.3892/ijo.2013.1884
Zhang, 2009, Expression of Beclin1 in osteosarcoma and the effects of down-regulation of autophagy on the chemotherapeutic sensitivity, J Huazhong Univ Sci Technolog Med Sci, 29, 737, 10.1007/s11596-009-0613-3
Coupienne, 2011, RIP3 expression induces a death profile change in U2OS osteosarcoma cells after 5-ALA-PDT, Lasers Surg Med, 43, 557, 10.1002/lsm.21088
Huang, 2012, HMGB1 promotes drug resistance in osteosarcoma, Cancer Res, 72, 230, 10.1158/0008-5472.CAN-11-2001
Huang, 2012, Targeting HMGB1-mediated autophagy as a novel therapeutic strategy for osteosarcoma, Autophagy, 8, 275, 10.4161/auto.8.2.18940
Pillai, 2007, Repression of protein synthesis by miRNAs: how many mechanisms?, Trends Cell Biol, 17, 118, 10.1016/j.tcb.2006.12.007
Lu, 2005, MicroRNA expression profiles classify human cancers, Nature, 435, 834, 10.1038/nature03702
Volinia, 2006, A microRNA expression signature of human solid tumors defines cancer gene targets, Proc Natl Acad Sci USA, 103, 2257, 10.1073/pnas.0510565103
Nakatani, 2012, miR-34a predicts survival of Ewing’s sarcoma patients and directly influences cell chemo-sensitivity and malignancy, J Pathol, 226, 796, 10.1002/path.3007
Gougelet, 2011, Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response, Int J Cancer, 129, 680, 10.1002/ijc.25715
Song, 2009, Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells, Oncogene, 28, 4065, 10.1038/onc.2009.274
Song, 2010, Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells, Mol Cancer, 9, 96, 10.1186/1476-4598-9-96
Cai, 2012, miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma, Oncol Rep, 28, 1764, 10.3892/or.2012.1995
Makino, 1959, The role of tumor stem-cells in regrowth of the tumor following drastic applications, Acta Unio Int Contra Cancrum, 15, 196
Bonnet, 1997, Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, Nat Med, 3, 730, 10.1038/nm0797-730
Ignatova, 2002, Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro, Glia, 39, 193, 10.1002/glia.10094
Singh, 2003, Identification of a cancer stem cell in human brain tumors, Cancer Res, 63, 5821
Liu, 2011, Cancer stem cells in osteosarcoma: recent progress and perspective, Acta Oncol, 50, 1142, 10.3109/0284186X.2011.584553
Woodward, 2008, Cancer stem cells: markers or biomarkers?, Cancer Metastasis Rev, 27, 459, 10.1007/s10555-008-9130-2
Vangipuram, 2010, Resistance of stem-like cells from neuroblastoma cell lines to commonly used chemotherapeutic agents, Pediatr Blood Cancer, 54, 361, 10.1002/pbc.22351
Di Fiore, 2009, Identification and expansion of human osteosarcoma-cancer-stem cells by long-term 3-aminobenzamide treatment, J Cell Physiol, 219, 301, 10.1002/jcp.21667
Fujii, 2009, Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines, Int J Oncol, 34, 1381
Honoki, 2010, Possible involvement of stem-like populations with elevated ALDH1 in sarcomas for chemotherapeutic drug resistance, Oncol Rep, 24, 501, 10.3892/or_00000885
Martins-Neves, 2012, Therapeutic implications of an enriched cancer stem-like cell population in a human osteosarcoma cell line, BMC Cancer, 12, 139, 10.1186/1471-2407-12-139
Chou, 2005, Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience, Cancer, 104, 2214, 10.1002/cncr.21417
Alberts, 2004, Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials, Semin Oncol, 31, S53, 10.1053/j.seminoncol.2004.08.010